Kiritoshi Takaki, Ji Guangchen, Neugebauer Volker
Department of Pharmacology and Neuroscience.
Department of Pharmacology and Neuroscience, Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center (TTUHSC), School of Medicine, Lubbock, Texas 79430-6592
J Neurosci. 2016 Jan 20;36(3):837-50. doi: 10.1523/JNEUROSCI.4047-15.2016.
The medial prefrontal cortex (mPFC) serves executive functions that are impaired in neuropsychiatric disorders and pain. Underlying mechanisms remain to be determined. Here we advance the novel concept that metabotropic glutamate receptor 5 (mGluR5) fails to engage endocannabinoid (2-AG) signaling to overcome abnormal synaptic inhibition in pain, but restoring endocannabinoid signaling allows mGluR5 to increase mPFC output hence inhibit pain behaviors and mitigate cognitive deficits. Whole-cell patch-clamp recordings were made from layer V pyramidal cells in the infralimbic mPFC in rat brain slices. Electrical and optogenetic stimulations were used to analyze amygdala-driven mPFC activity. A selective mGluR5 activator (VU0360172) increased pyramidal output through an endocannabinoid-dependent mechanism because intracellular inhibition of the major 2-AG synthesizing enzyme diacylglycerol lipase or blockade of CB1 receptors abolished the facilitatory effect of VU0360172. In an arthritis pain model mGluR5 activation failed to overcome abnormal synaptic inhibition and increase pyramidal output. mGluR5 function was rescued by restoring 2-AG-CB1 signaling with a CB1 agonist (ACEA) or inhibitors of postsynaptic 2-AG hydrolyzing enzyme ABHD6 (intracellular WWL70) and monoacylglycerol lipase MGL (JZL184) or by blocking GABAergic inhibition with intracellular picrotoxin. CB1-mediated depolarization-induced suppression of synaptic inhibition (DSI) was also impaired in the pain model but could be restored by coapplication of VU0360172 and ACEA. Stereotaxic coadministration of VU0360172 and ACEA into the infralimbic, but not anterior cingulate, cortex mitigated decision-making deficits and pain behaviors of arthritic animals. The results suggest that rescue of impaired endocannabinoid-dependent mGluR5 function in the mPFC can restore mPFC output and cognitive functions and inhibit pain. Significance statement: Dysfunctions in prefrontal cortical interactions with subcortical brain regions, such as the amygdala, are emerging as important players in neuropsychiatric disorders and pain. This study identifies a novel mechanism and rescue strategy for impaired medial prefrontal cortical function in an animal model of arthritis pain. Specifically, an integrative approach of optogenetics, pharmacology, electrophysiology, and behavior is used to advance the novel concept that a breakdown of metabotropic glutamate receptor subtype mGluR5 and endocannabinoid signaling in infralimbic pyramidal cells fails to control abnormal amygdala-driven synaptic inhibition in the arthritis pain model. Restoring endocannabinoid signaling allows mGluR5 activation to increase infralimbic output hence inhibit pain behaviors and mitigate pain-related cognitive deficits.
内侧前额叶皮质(mPFC)执行的功能在神经精神疾病和疼痛中会受损。其潜在机制仍有待确定。在此,我们提出了一个新的概念,即代谢型谷氨酸受体5(mGluR5)无法激活内源性大麻素(2-AG)信号来克服疼痛中异常的突触抑制,但恢复内源性大麻素信号可使mGluR5增加mPFC输出,从而抑制疼痛行为并减轻认知缺陷。在大鼠脑片的边缘下内侧前额叶皮质的V层锥体细胞上进行了全细胞膜片钳记录。使用电刺激和光遗传学刺激来分析杏仁核驱动的mPFC活动。一种选择性mGluR5激活剂(VU0360172)通过内源性大麻素依赖性机制增加锥体细胞输出,因为细胞内抑制主要的2-AG合成酶二酰甘油脂肪酶或阻断CB1受体可消除VU0360172的促进作用。在关节炎疼痛模型中,mGluR5激活无法克服异常的突触抑制并增加锥体细胞输出。通过用CB1激动剂(ACEA)或突触后2-AG水解酶ABHD6(细胞内WWL70)和单酰甘油脂肪酶MGL(JZL184)的抑制剂恢复2-AG-CB1信号,或通过用细胞内苦味毒素阻断GABA能抑制,可挽救mGluR5功能。在疼痛模型中,CB1介导的去极化诱导的突触抑制(DSI)也受损,但可通过联合应用VU0360172和ACEA来恢复。将VU0360172和ACEA立体定向共同注射到边缘下皮质而非前扣带回皮质中,可减轻关节炎动物的决策缺陷和疼痛行为。结果表明,挽救mPFC中受损的内源性大麻素依赖性mGluR5功能可恢复mPFC输出和认知功能并抑制疼痛。意义声明:前额叶皮质与杏仁核等皮质下脑区相互作用的功能障碍在神经精神疾病和疼痛中日益成为重要因素。本研究在关节炎疼痛动物模型中确定了一种新的机制和挽救内侧前额叶皮质功能受损的策略。具体而言采用了光遗传学、药理学、电生理学和行为学的综合方法,提出了一个新的概念,即在关节炎疼痛模型中,边缘下锥体细胞中代谢型谷氨酸受体亚型mGluR5和内源性大麻素信号的破坏无法控制杏仁核驱动的异常突触抑制。恢复内源性大麻素信号可使mGluR5激活增加边缘下输出,从而抑制疼痛行为并减轻与疼痛相关的认知缺陷。